Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients.

Parra-Bonilla G, Arboleda G, Yunis J, Solano E, Pardo R, Arango G, Hedmont D, Arboleda H.

Neurosci Lett. 2003 Oct 9;349(3):159-62.

PMID:
12951193
2.

Apolipoprotein E promoter polymorphisms (-491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population.

Lynch CA, Brazil J, Cullen B, Coakley D, Gill M, Lawlor BA, Hawi Z.

Ir J Med Sci. 2008 Mar;177(1):29-33. Epub 2007 Dec 5.

PMID:
18057979
3.

The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.

Town T, Paris D, Fallin D, Duara R, Barker W, Gold M, Crawford F, Mullan M.

Neurosci Lett. 1998 Aug 14;252(2):95-8.

PMID:
9756330
4.

Apolipoprotein E promoter polymorphisms and risk of Alzheimer's disease: evidence from meta-analysis.

Xin XY, Ding JQ, Chen SD.

J Alzheimers Dis. 2010;19(4):1283-94. doi: 10.3233/JAD-2010-1329.

PMID:
20061606
5.

Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.

Helisalmi S, Hiltunen M, Valonen P, Mannermaa A, Koivisto AM, Lehtovirta M, Ryynänen M, Soininen H.

J Neurol. 1999 Sep;246(9):821-4.

PMID:
10525981
6.

Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients.

Zill P, Engel R, Hampel H, Behrens S, Bürger K, Padberg F, Stübner S, Möller HJ, Ackenheil M, Bondy B.

Eur Arch Psychiatry Clin Neurosci. 2001;251(1):24-8.

PMID:
11315514
7.

APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.

Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, Arriaga A, Stern Y, Lantigua R, Shachter N, Mayeux R.

Arch Neurol. 2004 Sep;61(9):1434-9. Erratum in: Arch Neurol. 2005 Feb;62(2):332.

PMID:
15364690
8.

Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease.

Halimi G, Duplan L, Bideau C, Iniesta D, Berthézène P, Oddoze C, Verdier JM, Michel B, Bergé-Lefranc JL.

Neuroreport. 2000 Nov 9;11(16):3599-601.

PMID:
11095526
9.

Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease.

Wang JC, Kwon JM, Shah P, Morris JC, Goate A.

Neurology. 2000 Dec 12;55(11):1644-9.

PMID:
11113217
10.

Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study.

Roks G, Cruts M, Houwing-Duistermaat JJ, Dermaut B, Serneels S, Havekes LM, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM.

Am J Med Genet. 2002 Jul 8;114(5):570-3.

PMID:
12116196
11.

APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population.

Zurutuza L, Verpillat P, Raux G, Hannequin D, Puel M, Belliard S, Michon A, Pothin Y, Camuzat A, Penet C, Martin C, Brice A, Campion D, Clerget-Darpoux F, Frebourg T.

Eur J Hum Genet. 2000 Sep;8(9):713-6.

12.

Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene.

Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, García MA, Lendon CL, Han SW, Morris JC, Vázquez J, Goate A, Valdivieso F.

Hum Mol Genet. 1998 Nov;7(12):1887-92.

PMID:
9811931
13.

Contribution of APOE promoter polymorphisms to Alzheimer's disease risk.

Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, Harris JM, Artiga MJ, Hernandez D, Kwon JM, Frigard B, Petersen RC, Cumming AM, Pasquier F, Sastre I, Tienari PJ, Frank A, Sulkava R, Morris JC, St Clair D, Mann DM, Wavrant-DeVrièze F, Ezquerra-Trabalon M, Amouyel P, Hardy J, Haltia M, Valdivieso F, Goate AM, Pérez-Tur J, Lendon CL, Chartier-Harlin MC.

Neurology. 2002 Jul 9;59(1):59-66.

PMID:
12105308
14.

The --491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer's disease.

Alvarez-Arcaya A, Combarros O, Llorca J, Sánchez-Guerra M, Berciano J, Fernández-Luna JL.

Neurosci Lett. 2001 May 25;304(3):204-8.

PMID:
11343837
15.
16.

ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population.

Juhász A, Palotás A, Janka Z, Rimanóczy A, Palotás M, Bódi N, Boda K, Zana M, Vincze G, Kálmán J.

Neurochem Res. 2005 May;30(5):591-6.

PMID:
16176061
17.

Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia?

Thome J, Gewirtz JC, Sakai N, Zachariou V, Retz-Junginger P, Retz W, Duman RS, Rösler M.

Neurosci Lett. 1999 Oct 15;274(1):37-40.

PMID:
10530514
18.

Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe.

Capurso C, Solfrizzi V, D'Introno A, Colacicco AM, Capurso SA, Capurso A, Panza F.

Exp Gerontol. 2004 Oct;39(10):1567-73. Review.

PMID:
15501028
19.

Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease.

Capurso C, Solfrizzi V, Colacicco AM, D'Introno A, Frisardi V, Imbimbo BP, Lorusso M, Vendemiale G, Denitto M, Santamato A, Seripa D, Pilotto A, Fiore P, Capurso A, Panza F.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):177-82. doi: 10.1016/j.pnpbp.2009.10.022. Epub 2009 Nov 6.

PMID:
19897004
20.

Supplemental Content

Support Center